Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $20.8 million.

  • Foghorn Therapeutics' Non-Current Assets fell 4387.15% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year decrease of 3292.14%. This contributed to the annual value of $34.4 million for FY2024, which is 2482.56% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Non-Current Assets of $20.8 million as of Q3 2025, which was down 4387.15% from $22.4 million recorded in Q2 2025.
  • Foghorn Therapeutics' Non-Current Assets' 5-year high stood at $64.6 million during Q1 2021, with a 5-year trough of $20.8 million in Q3 2025.
  • Over the past 5 years, Foghorn Therapeutics' median Non-Current Assets value was $49.1 million (recorded in 2023), while the average stood at $47.4 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Non-Current Assets tumbled by 394.04% in 2021, and later plummeted by 4387.15% in 2025.
  • Foghorn Therapeutics' Non-Current Assets (Quarter) stood at $60.2 million in 2021, then fell by 11.17% to $53.5 million in 2022, then dropped by 14.49% to $45.7 million in 2023, then decreased by 24.83% to $34.4 million in 2024, then plummeted by 39.37% to $20.8 million in 2025.
  • Its Non-Current Assets was $20.8 million in Q3 2025, compared to $22.4 million in Q2 2025 and $33.3 million in Q1 2025.